Researchers have been excited about this new drug, a groundbreaking dual compound showing remarkable results in initial trials for size management. It acts by targeting both pathways : GLP-1 and GIP, these, when activated , support influence hunger and improve metabolism . Early findings demonstrate substantial body reduction and likely improvement